A catalog of HLA type, HLA expression, and neoepitope candidates in human cancer cell lines

OncoImmunology

Volumn 3, Issue 8, 2014, Pages

  Boegel, Sebastian ^a   Löwer, Martin ^a   Bukur, Thomas ^a   Sahin, Ugur ^a,b   Castle, John C ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BIONTECH AG   (Germany)

Author keywords

Cancer cell lines; HLA expression; HLA type; Immunotherapy; Neoepitopes; RNA Seq; Somatic mutations

Indexed keywords

EPITOPE; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; TRANSCRIPTOME;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; GENE LOCUS; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NEXT GENERATION SEQUENCING; RNA SEQUENCE;

EID: 84921693763     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.954893     Document Type: Article

References (47)

1. Gillet, J.-P. Varma, S, Gottesman, MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013; 105:452-8; PMID:23434901; http://dx.doi.org/10.1093/jnci/djt007
2. Sharma SV Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010; 10:241-53; PMID:20300105; http://dx.doi.org/10.1038/ nrc2820
3. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39:D945-50; PMID:20952405; http://dx.doi.org/10.1093/nar/gkq929
4. Barretina, J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7; PMID:22460905; http://dx.doi.org/10.1038/nature11003
5. Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 2014; 15:190; PMID:24621249; http://dx.doi. org/10.1186/1471-2164-15-190
6. Kim Y. Sette A, Peters B. Applications for T-cell epitope queries and tools in the immune epitope database and analysis resource, J Immunol Methods 2011; 374:62-9; PMID:21047510; http://dx.doi.org/10.1016/j.jim.2010.10.010
7. Dutoit V. Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135:1042-54; PMID:22418738; http:// dx.doi.org/10.1093/brain/aws042
8. Khalili JS, Hanson RW, Szallasi Z. In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. Oncoimmunology 2012; 1:1281-9; PMID:23243591; http://dx.doi.org/ 10.4161/onci.21511
9. Warren RL, Holt RA. A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol 2010; 71:245-54; PMID:20035814; http://dx.doi.org/10.1016/j.humimm.2009.12.007
10. Segal, N. H. Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68:889-92; PMID:18245491; http://dx.doi.org/10.1158/0008-5472.CAN-07-3095
11. Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91; PMID: 22237626; http://dx.doi.org/10.1158/0008-5472. CAN-11-3722
12. Rammensee H-G, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines 2013; 12:1211-17; PMID:24090147; http://dx.doi.org/10.1586/ 14760584.2013.836911
13. Helmberg W, Dunivin R, Feolo M. The reagent database at dbMHC. Tissue Antigens 2004; 63:142-8; PMID:14705985; http://dx.doi.org/10.1111/j.1399-0039.2004.00163.x
14. Band V. Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, Connolly J, Sager R. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res 1990; 50:7351-7; PMID:1977518
15. Boegel S. Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, Türeci O, Diken M, Castle JC, Sahin U. HLA typing from RNA-Seq sequence reads. Genome Med 2013; 4:102; http://dx.doi.org/10.1186/gm403
16. Teh M, Hui KM. Modulation of MHC gene expression in human breast carcinoma cells by hormones. J Immunogenet 1989; 16:397-405 ; PMID: 2639911; http://dx.doi.org/10.1111/j.1744-313X.1989.tb00487.x
17. Algarra I Garćia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection f tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 3:904-10; PMID:15069585; http://dx.doi.org/10.1007/s00262-004-0517-9
18. Atkins D, Ferrone S, Schmahl GE, Störkel, S, Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 2004; 171:885-9; PMID:14713847; http://dx.doi.org/10.1097/01.ju.0000094807.95420.fe
19. Britten CM, Meyer RG, Kreer T, Drexler I, Wölfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(C) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002; 259:95-110; PMID:11730845; http://dx.doi.org/10.1016/S0022-1759(01)00499-9
20. Le Bouteiller P, Barakonyi A, Giustiniani J, Lenfant F, Marie-Cardine A, Aguerre-Girr M, Rabot M, Hilgert I, Mami-Chouaib F, Tabiasco J, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A 2002; 99:16963-68; PMID:12486241; http://dx.doi.org/ 10.1073/pnas.012681099
21. Ruiz-Cabello, F. et al. Molecular analysis of MHCclass-I alterations in human tumor cell lines. Int J Cancer Suppl 1991; 6:123-130; PMID:1906050; http:// dx.doi.org/10.1002/ijc.2910470723
22. Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mulé JJ. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 1994; 16:13-23; PMID:8081556; http://dx.doi.org/10.1097/ 00002371-199407000-00002
23. Schuler MM, Nastke M-D, Stevanovikć S. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol 2007; 409:75-93; PMID:18449993; http://dx.doi.org/10.1007/978-1-60327-118-9_5
24. Thomsen M, Lundegaard C, Buus S, Lund O, Nielsen M. MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics 2013; 65:655-65; PMID:23775223; http://dx.doi.org/10.1007/s00251-013-0714-9
25. Vigneron, N. Stroobant, V. Van den Eynde, Benoît J, van der Bruggen, Pierre. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013; 13:15; PMID:23882160
26. ItoD, Visus C, Hoffmann TK, Balz V, BierH, Appella E, Whiteside TL, Ferris RL, DeLeo AB. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201C squamous cell carcinomas of the head and neck. Int J Cancer 2007; 120:2618-24; PMID:17294448; http://dx.doi. org/10.1002/ijc.22584
27. Hughes P Marshall D, Reid Y, Parkes, H, Gelber C. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?. BioTechniques 2007; 43:575, 577-8, 581-2 passim: http://dx.doi. org/10.2144/000112598
28. Giacomini P, Giorda E, Pera C, Ferrara GB. An ID card for tumour cell lines: HLA typing can help. Lancet Oncol 2001; 2:658 ; PMID:11902535; http://dx.doi. org/10.1016/S1470-2045(01)00554-X
29. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-158; PMID: 17344846; http://dx.doi.org/10.1038/nature05610
30. Reva B. Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers. BMC Genomics 2013; 14:Suppl 3:S8; PMID:23819556; http://dx.doi.org/10.1186/1471-2164-14-S3-S8
31. Stratton MR Exploring the genomes of cancer cells: progress and promise. Science 2011; 331:1553-8; PMID:21436442; http://dx.doi.org/10.1126/science. 1204040
32. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
33. Matsushita, H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx.doi.org/10.1038/nature10755
34. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2014; 2(6):522-9; PMID:24894089; http://dx.doi.org/10.1158/2326-6066.CIR-13-0227
35. Kreiter S, Castle JC, Türeci Ö, Sahin U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 2012; 1:768-9; PMID:22934277; http://dx.doi.org/10.4161/onci.19727
36. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011; 9:e1001046; PMID: 21526222; http://dx.doi.org/10.1371/journal.pbio. 1001046.
37. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44:1111-6; PMID:22941189; http://dx.doi.org/10.1038/ng.2405
38. Schomburg I, Chang A, Placzek S, Söhngen C, Rother M, Lang M, Munaretto C, Ulas S, Stelzer M, Grote A, et al. BRENDA in 2013: integrated reactions, kinetic data, enzyme function data, improved disease classification: new options and contents in BRENDA. Nucleic Acids Res 2013; 41:D764-72; PMID:23203881; http://dx.doi.org/10.1093/nar/gks1049
39. Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC 3rd, Stroncek D, Marincola FM. HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 2005; 3:11; PMID:15748285; http://dx.doi.org/10.1186/1479-5876-3-11
40. Robinson, J. Halliwell JA, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res 2013; 41:D1222-7; PMID:23080122; http://dx.doi.org/10.1093/nar/gks949
41. Public Health England.HLA-Typed Collection. Available at http://www.phe-culturecollections.org.uk/products/ celllines/hlatyped/browse.jsp (last access: 21.02.2014)
42. Paunić V, Gragert L, Madbouly A, Freeman J, Maiers M. Measuring ambiguity in HLA typing methods. PLoS ONE 2012; 7:e43585; PMID:22952712; http://dx.doi.org/10.1371/journal.pone.0043585
43. Mortazavi A, Williams BA, McCue K, Schaeffer, L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nat Methods 2008; 5:621-8; PMID:18516045; http://dx.doi.org/10.1038/nmeth.1226
44. Lundegaard C. Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008; 36:W509-12; PMID: 18463140; http://dx.doi.org/10.1093/nar/gkn202
45. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 6:132; PMID:15927070; http://dx.doi.org/10.1186/1471-2105-6-132
46. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153:5586-92; PMID:7527444
47. Paul S. Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptidebinding repertoires of different size, affinity, and immunogenicity. J Immunol 2013; 191:5831-9; PMID: 24190657; http://dx.doi.org/10.4049/jimmunol.1302101